

Clinical impact of amyloid PET in memory clinic: A two-year longitudinal real-world study in Taiwan



P4-13

Chia-Ju Chou, Yi-Fang Chuang, Yen-Ling Chiu, Shu-Ching Wu, Yu-Ming Fan, Yi-Chien Liu*

1. Department of Neurology, Cardinal Tien Hospital, Taipei, Taiwan

2. Medical School of Fu-Jen University, Taipei, Taiwan

Amyloid PET changes the clinical diagnosis of 49.5% of the memory clinic cohort, mostly exclude the diagnosis of AD. Amygdala and inferior parietal atrophy strongly predict the amyloid positivity.

INTRODUCTION	METHODS	RESULTS	CONCLUSIONS	REFERENCES
In this study, we established and prospectively validated an optimal Florbetaben centiloid threshold in a consecutively recruited Taiwanese cohort.  Amyloid PET ■ Negative ■ Positive Figure 1.	- This prospective longitudinal cohort study enrolled 206 participants with cognitive complaints or objective cognitive impairment who were evaluated at the Memory Clinic of Cardinal Tien Hospital in Taipei, Taiwan, between 2021 and 2023. - At baseline, the clinical spectrum included 14 cognitively normal older adults, 47 participants with subjective cognitive decline (SCD), 140 with mild cognitive impairment (MCI; 127 amnesic, 13 non-amnesic), and 5 with dementia.	- Optimal cohort-derived threshold of 21.60, yielding a sensitivity of 91.18%, a specificity of 99.04%, and an AUC of 0.98 (Figure 1). - Among amyloid-positive participants, linear regression analyses revealed that higher continuous CL burden was associated with lower MMSE ($\beta = -0.43$, $P < 0.001$) and disease severity (baseline CDR-SB: $\beta = 0.31$, $P < 0.001$) (Figure 2).	- Baseline amyloid burden on the CL scale provided a continuous and clinically prognostic signal within the early AD cases. - the present study contributes a prospectively validated CL threshold and longitudinal real-world evidence from Taiwanese memory clinic cohort.  Amyloid PET ■ Negative ■ Positive Figure 2.	- Lopes Alves I, Collij LE, Altomare D, et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimers Dement.</i> 2020;16(5):750-758. - De Wilde A, Van Der Flier WM, Pelkmans W, et al. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. <i>JAMA Neurol.</i> 2018;75(9):1062. CONTACT  Dr. Yi-Chien Liu E-mail: milkgen@gmail.com 